EE362 A Budget Impact Analysis of Pertuzumab, Trastuzumab, and Chemotherapy in the Neoadjuvant Setting for HER2-Positive High-Risk Early Breast Cancer Patients: Insights from the Tuscany Regional Health Care System Perspective
Abstract
Authors
I.C. Antonazzo C. Bengala L. Biganzoli L.G. Mantovani A. Michelotti P. Cortesi